These CTLs recognized and had cytotoxic activity against PRAME-expressing tumor cell lines and primary CML cells, demonstrating the potential of PRAME in cancer vaccine development for CML treatment. This evidence concerns the gene PRAME and chronic myelogenous leukemia, BCR-ABL1 positive.